Results 121 to 130 of about 50,773 (265)
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter +20 more
wiley +1 more source
Prompt recurrence of granuloma annulare upon Janus kinase inhibitor discontinuation. [PDF]
Haveric A, Zhao P, Markeson CD, Hsu S.
europepmc +1 more source
Non‐invasive scalp tape‐strip RNA sequencing captures core immune and follicular molecular signatures in alopecia areata. Tape‐strip transcriptomic profiles reflect disease severity and treatment response to baricitinib, with concordance to scalp biopsy‐derived signatures.
Carmen Mochón‐Jiménez +10 more
wiley +1 more source
Use of Janus Kinase Inhibitor Upadacitinib in Microscopic Colitis. [PDF]
Mumm B, Stein DJ.
europepmc +1 more source
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car +3 more
wiley +1 more source
Resolution of Hashimoto thyroiditis with Janus kinase inhibitor therapy in a patient with alopecia universalis. [PDF]
Trost SU, Radulescu A.
europepmc +1 more source
HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi +8 more
wiley +1 more source
Early Intervention With Biologics for Asthma Remission: Promising or Premature?
Respirology, EarlyView.
Santi Nolasco +2 more
wiley +1 more source
Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy
The gut microbiome modulates ulcerative colitis pharmacotherapy through microbial drug metabolism, immune regulation and altered drug bioavailability. Microbial composition influences response to aminosalicylates, corticosteroids, immunomodulators, biologics and small molecules, while microbiome‐targeted therapies show emerging promise.
Kate Collins +6 more
wiley +1 more source
Janus Kinase Inhibitor Upadacitinib in Elderly-Onset Rheumatoid Arthritis With Hip Osteoarthritis: A Case Report. [PDF]
Sanji Y +5 more
europepmc +1 more source

